Last reviewed · How we verify
Topical Fluorometholone
Fluorometholone is a topical corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.
Fluorometholone is a topical corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Inflammatory and allergic conditions of the palpebral and bulbar conjunctiva, lid, and anterior segment of the eye, Post-operative inflammation following ocular surgery, Steroid-responsive inflammatory conditions of the anterior segment.
At a glance
| Generic name | Topical Fluorometholone |
|---|---|
| Sponsor | Navy Medical Center San Diego |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Fluorometholone reduces inflammation by inhibiting the production of inflammatory mediators and suppressing immune cell activity at the ocular surface and anterior segment. It decreases vasodilation, edema, and cellular infiltration characteristic of inflammatory eye conditions. The drug is applied topically to achieve local anti-inflammatory effects with minimal systemic absorption.
Approved indications
- Inflammatory and allergic conditions of the palpebral and bulbar conjunctiva, lid, and anterior segment of the eye
- Post-operative inflammation following ocular surgery
- Steroid-responsive inflammatory conditions of the anterior segment
Common side effects
- Elevated intraocular pressure
- Posterior subcapsular cataract formation
- Local irritation or stinging
- Allergic contact dermatitis
Key clinical trials
- Fluorometholone Study (PHASE2)
- Efficacy and Safety of Dextenza Compared to Topical Fluorometholone in Patients With Ocular Rosacea (PHASE4)
- Comparison of the Postoperative Use of Dextenza vs a Standard Regimen After PRK (PHASE4)
- Topical Insulin Versus Autologous Serum After Corneal Surgeries (PHASE1)
- The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements (PHASE2, PHASE3)
- Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye (NA)
- The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization (PHASE1, PHASE2)
- Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |